• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

    65.92 -0.99 (-1.48%)
    Streaming Delayed Price Updated: 3:17 PM EST, Jan 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Arrowhead Pharmaceuticals, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    News headline image
    Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
    From Arrowhead Pharmaceuticals
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.